Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the chronic obstructive pulmonary disease (COPD) drug market will nearly double from $5.8 billion in 2006 to $10.6 billion in 2016. According to the new Pharmacor report entitled Chronic Obstructive Pulmonary Disease, improvements in COPD diagnosis, the aging demographics of the populations, and increased use of more-expensive maintenance therapies will drive this growth.

"The increased uptake of premium-priced current and emerging COPD maintenance therapies such as GlaxoSmithKline's Advair/Seretide, Boehringer Ingelheim/Pfizer's Spiriva, GlaxoSmithKline/Theravance's Beyond Advair combination agent, and Novartis's indacaterol/glycopyrronium will be driven by growing acceptance of these drugs," said Regina Cebula, analyst at Decision Resources. "The future trend of COPD management will be toward greater symptom control, fewer exacerbations, and improved quality of life through the use of more convenient and effective treatments."

The COPD market has historically been dominated by large companies - including Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Novartis, Schering-Plough, and Pfizer - because the development of inhaled drugs involves significant regulatory hurdles and a large sales force is needed to market drugs to both pulmonologists and primary care physicians. However, smaller players - including Sepracor, Chiesi, and Nycomed - have more recently and successfully established themselves in the market.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall OF Decision Resources, Inc.,

United Gunning for Growth in Washington Market

View Now